Atlas Bio
Basel, Switzerland
◆ Total Raised
$12.5M
◆ Stage
seed
◆ Location
Basel, Switzerland
◆ Founded
2024
◆ Team size
1-10
◆ Links
◆ About Atlas Bio
Swiss tech-bio firm developing a foundational AI model to run in silico clinical trials, simulating patient-level efficacy and safety signals to de-risk drug development and replace animal testing.
◆ What sets it apart
Its foundation model simulates heterogeneous, patient-level human responses across virtual clinical trials, enabling drug efficacy and safety assessment before Phase II and potentially reducing animal experimentation.[1][2]
◆ Sectors
◆ Business
ModelSaaS
CustomerBiopharmaceutical companies and biotech firms developing or evaluating drug candidates
◆ Notable
- Launched from stealth with a $10 million seed round led by Creandum.[2]
- Raised a total of $12.5 million including a pre-seed round led by First Momentum Ventures and LEA Partners.[2]
- Developed in silico clinical-trial simulations that can be completed in approximately 12 weeks.[2]
- Ran a virtual asthma trial across 78 patients, predicting each patient's transcriptomic treatment response.[1]
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Atlas Bio do?
Swiss tech-bio firm developing a foundational AI model to run in silico clinical trials, simulating patient-level efficacy and safety signals to de-risk drug development and replace animal testing.
Where is Atlas Bio based?
Atlas Bio is based in Basel, Switzerland, founded in 2024.
How much has Atlas Bio raised?
Atlas Bio has raised $12.5M in tracked funding and is currently at the seed stage.
Who has invested in Atlas Bio?
Investors in Atlas Bio include Creandum, First Momentum Ventures and LEA Partners.